Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995

Substitute for form 1449/PTO

JUL 2 5 2006

INFORMATION DIS STATEMENT BY APPER

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/772,963 (Conf. #5299)		
Filing Date	5 February 2004		
First Named Inventor	David P. BINGAMAN		
Art Unit	1617		
Examiner Name	Hui, San Ming R.		
Attorney Docket Number	2471 US		

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/SH/	1A	US- 5,371,078	12/06/1994	Clark et al.	
7011/	·1B	^{US-} 5,646,136	07/08/1997	Petrow et al.	
	1C	US- 6,726,918	04/27/2004	Wong et al.	
	1D	US- 2004/0127472 A1	07/01/2004	Jerdan et al.	
1//	1E	^{US-} 2006/0074061 A1	04/06/2006	Bingaman et al.	
		US-			
<u> </u>		US-			
	 	US-		·	
	<u> </u>	US-			
	 	US-			
		US-			
		US-			
	1	us-			
	1	US-			
		US-			
		US-		1:	
		US-			
		US-			
	1	US-			

		FOREIG	GN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	τ•
		Country Code ³ Number ⁴ Kind Code ⁸ (if known)	MM-DD-YYYY			├ ─
/SH/	1F	WO 97/41844 A1	11/13/1997	Alcon Laboratories, Inc.		ــــــ
<u> </u>	1G	WO 98/19649 A2 and A3	05/14/1998	The Children's Medical		↓
$-\Psi$	11	WO 2004/0736708 A2 and A3	09/02/2004	Alcon, Inc.		
-						┼┈
						<u> </u>
	1					1

		Date	0.7/0.7/0.07
Examiner	Con Mina Livit	Considered	05/25/2007
Signature	/San Ming Hui/	Considered	00/20/2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Uspto Patent Documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language ² See Kinds Codes of Standard ST.3). ⁴ For

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI
	e required to respond to a collection of information unless it contains a valid OMB control number
Under the Paperwork Reduction Act of 1995, no persons are	Complete if Known

		0. 1000 1	Complete if Known			
e for form 1449/PTO			Application Number	10/772,963 (Conf. #5299)		
RMATIO	N DIS	CLOSURE	Filing Date	5 February 2004		
			First Named Inventor	David P. BINGAMAN		
			Art Unit	1617		
(Use as many si	heets as ne	cessary)	Examiner Name	Hui, San Ming R.		
2	of	2	Attorney Docket Number	2471 US		
	PRMATION TEMENT	PERMATION DISC TEMENT BY AF	PER FORMATION DISCLOSURE TEMENT BY APPLICANT (Use as many sheets as necessary)	PRMATION DISCLOSURE TEMENT BY APPLICANT (Use as many sheets as necessary) Application Number Filing Date First Named Inventor Art Unit Examiner Name	Application Number 10/772,963 (Conf. #5299) PRMATION DISCLOSURE Filing Date 5 February 2004 TEMENT BY APPLICANT First Named Inventor David P. BINGAMAN Art Unit 1617 Examiner Name Hui, San Ming R.	

		NON PATENT LITERATURE DOCUMENTS	· · ·
Examiner nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SH/	2A	Jonas JB, et al., Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularization, J. Cataract Refract. Surg. 28: 2040-2041 (2002)	
	2B	Karmel, Miriam, "AMD Under the Scope", AM ACADEMY OF OPHTHALMOLOGY	
	2C	National Institutes of Health (NIH), "A Novel, Preservative-Free Steroid Formulation for Use as an Anti-Inflammatory"	
	2D	Penn et al., The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity, IOVS, 42, 1, 282-289 (Jan 2001)	
V	2E	Regenera Limited, Investor update August 2004	
	2F		
	2G		
	2H		
	21		
	2J		

Examiner Signature	/San Ming Hui/	Date Considered	05/25/2007
Signature			to the state of the second polymers and polymers

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.